Immix Biopharma, Inc. SEC filings IMMX
Immix Biopharma, Inc. has 244 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| FWP | Free writing prospectus | Sep 29, 2026 | — |
| 424B5 | Prospectus supplement | Sep 29, 2026 | — |
| 424B5 | Prospectus supplement | May 21, 2026 | — |
| FWP | Free writing prospectus | May 21, 2026 | — |
| S-8 | Employee stock plan registration | Mar 25, 2026 | — |
| 424B5 | Prospectus supplement | Mar 25, 2026 | — |
| S-3 | Shelf registration | Jan 9, 2026 | — |
| 424B5 | Prospectus supplement | Dec 8, 2025 | — |
| FWP | Free writing prospectus | Dec 8, 2025 | — |
| S-3 | Shelf registration | Oct 6, 2025 | — |
| 424B5 | Prospectus supplement | Jun 3, 2025 | — |
| S-8 | Employee stock plan registration | Jul 22, 2024 | — |
| S-8 | Employee stock plan registration | Feb 20, 2024 | — |
| 424B5 | Prospectus supplement | Feb 7, 2024 | — |
| 424B5 | Prospectus supplement | Feb 5, 2024 | — |
| S-3 | Shelf registration | Sep 25, 2023 | — |
| 424B5 | Prospectus supplement | Jul 14, 2023 | — |
| S-8 | Employee stock plan registration | Jun 13, 2023 | — |
| 424B5 | Prospectus supplement | Mar 22, 2023 | — |
| S-3 | Shelf registration | Jan 3, 2023 | — |
| FWP | Free writing prospectus | May 27, 2022 | — |
| S-1 | Registration statement | May 27, 2022 | — |
| S-8 | Employee stock plan registration | Jan 25, 2022 | — |
| 424B4 | Prospectus | Dec 17, 2021 | — |
| FWP | Free writing prospectus | Dec 1, 2021 | — |
| S-1/A | Amended registration statement | Nov 4, 2021 | — |
| S-1/A | Amended registration statement | Oct 28, 2021 | — |
| S-1/A | Amended registration statement | Oct 15, 2021 | — |
| S-1/A | Amended registration statement | Oct 6, 2021 | — |
| S-1 | Registration statement | Sep 17, 2021 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1873835
- Former names
- Immix Biopharma, Inc. (until Oct 27, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.